Riot Platforms, Inc. — Call Transcript 2010

Jul 20, 2010

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported) July 19, 2010

AspenBio Pharma, Inc.

(Exact name of Registrant as specified in its charter)

Colorado	001-33675	84-155338
(State
or other jurisdiction of incorporation)	(Commission
File Number)	(I.R.S.
Employer Identification No.)

| 1585
South Perry Street Castle
Rock, Colorado | 80104 |
| --- | --- |
| (Address
of principal executive offices) | (Zip
Code) |

Registrant’s telephone number, including area code (303) 794-2000

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

EFPlaceholder o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01. Other Events.

On July 19, 2010, AspenBio Pharma, Inc. (the “Company”) issued a press release titled — “AspenBio Pharma Reports AppyScore™ ELISA-based Pivotal Trial Results and Outlines Plans for AppyScore Cassette-based Test.” The press release is provided as Exhibit 99.1 to this Form 8-K.

On July 20, 2010, AspenBio Pharma, Inc. (the “Company”) hosted an investor update call — “AspenBio Pharma July 2010 Conference Call.” The script for this call is provided as Exhibit 99.2 to this Form 8-K.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibits

99.1 Press release, dated July 19, 2010, issued by AspenBio Pharma, Inc. titled “AspenBio Pharma Reports AppyScore™ ELISA-based Pivotal Trial Results and Outlines Plans for AppyScore Cassette-based Test”

99.2 Investor conference call script dated July 20, 2010

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized

| AspenBio
Pharma, Inc. (Registrant) — /s/
Jeffrey G. McGonegal |
| --- |
| Name:
Jeffrey G. McGonegal |
| Title:
Chief Financial Officer |